Skip to main content

Table 2 The 25 IPA-pathways most significantly enriched for BMI-associated gene-specific transcripts in the SHIP-TREND/KORA F4 meta-analysis

From: Extensive alterations of the whole-blood transcriptome are associated with body mass index: results of an mRNA profiling study involving two large population-based cohorts

Defined gene expression signatures with assigned canonical IPA-pathways FDR for genes with BMI-associated mRNA levels (all genes/ positively associated/ negatively associated) Number of genes with BMI-associated mRNA levels (all genes/ positively associated/ negatively associated) FDR from permutation analysis
Erythrocyte-Reticulocyte Ratio Shift  
  EIF2 signaling 6.8 × 10-8/ 6.3 × 10-14/ 5.8 × 10-1 70/ 46/ 24 0.0002
  Mitochondrial dysfunction 1.0 × 10-5/ 3.6 × 10-8/ 3.2 × 10-1 58/ 34/ 24 0.0002
  Regulation of eIF4 and p70S6K signaling 1.7 × 10-5/ 4.5 × 10-6/ 1.3 × 10-1 55/ 29/ 26 0.0002
  mTOR signaling 5.4 × 10-4/ 1.1 × 10-2/ 6.9 × 10-2 60/ 26/ 34 0.0059
  Oxidative phosphorylation 7.9 × 10-4/ 4.9 × 10-8/ N. A. 34/ 25/ 9 0.0002
  Heme biosynthesis II 1.9 × 10-3/ 4.5 × 10-6/ N. A. 7/ 7/ 0 0.0002
Attenuated Insulin Signaling  
  PI3K/AKT signaling 1.7 × 10-5/ 3.6 × 10-1/ 6.9 × 10-4 49/ 15/ 34 0.0002
  Insulin receptor signaling 6.5 × 10-5/ 8.6 × 10-1/ 5.8 × 10-4 49/ 13/ 36 0.0002
  Hypoxia signaling in the cardiovascular system 6.5 × 10-5/ 4.5 × 10-1/ 6.9 × 10-4 30/ 9/ 21 0.0002
  Chronic myeloid leukemia signaling 1.5 × 10-4/ 4.5 × 10-1/ 1.7 × 10-3 38/ 12/ 26 0.0002
  Production of NO and ROS in macrophages 1.5 × 10-4/ N. A./ 4.3 × 10-6 62/ 9/ 53 0.0002
  Pancreatic adenocarcinoma signaling 1.5 × 10-4/ 7.6 × 10-1/ 7.4 × 10-4 42/ 12/ 30 0.0134
  ILK signaling 1.9 × 10-4/ 8.8 × 10-1/ 5.8 × 10-4 62/ 15/ 47 0.0002
  AMPK signaling 3.1 × 10-4/ 7.7 × 10-1/ 1.6 × 10-3 48/ 14/ 34 0.0026
  JAK-STAT signaling 3.1 × 10-4/ 8.8 × 10-1/ 6.9 × 10-4 31/ 7/ 24 0.0154
  Renal cell carcinoma signaling 3.1 × 10-4/ 6.8 × 10-1/ 2.1 × 10-3 30/ 9/ 21 0.0170
  Ceramide signaling 3.8 × 10-4/ 9.2 × 10-1/ 6.9 × 10-4 33/ 7/ 26 0.0026
  mTOR signaling 5.4 × 10-4/ 1.1 × 10-2/ 6.9 × 10-2 60/ 26/ 34 0.0059
  CTLA4 signaling in cytotoxic T lymphocytes 6.2 × 10-4/ 5.0 × 10-2/ 3.8 × 10-2 33/ 14/ 19 0.0002
  B cell receptor signaling 7.4 × 10-4/ 9.2 × 10-1/ 5.8 × 10-4 56/ 12/ 44 0.0002
  Prostate cancer signaling 7.9 × 10-4/ 9.2 × 10-1/ 8.5 × 10-4 32/ 7/ 25 0.0002
  Glioma signaling 7.9 × 10-4/ 4.5 × 10-1/ 7.6 × 10-3 36/ 12/ 24 0.0085
  Non-small cell lung cancer signaling 1.4 × 10-3/ 9.2 × 10-1/ 1.5 × 10-3 27/ 6/ 21 0.0002
  Cyclins and cell cycle regulation 2.0 × 10-3/ 1.9 × 10-1/ 4.1 × 10-2 30/ 12/ 18 0.0002
  PDGF signaling 2.0 × 10-3/ 9.0 × 10-1/ 1.7 × 10-3 30/ 7/ 23 0.1620
Reduced Protection against Oxidative Stress  
  NRF2-mediated oxidative stress response 3.5 × 10-5/ 8.7 × 10-1/ 8.5 × 10-4 60/ 17/ 43 0.0489
  1. The pathway “mTOR Signaling” is assigned to two signatures: “Erythrocyte-Reticulocyte Ratio Shift” (positively associated transcripts) and “Attenuated Insulin Signaling” (negatively associated transcripts). Benjamini-Hochberg-FDR-values < 0.01 are provided in bold. Permutation analysis was performed to evaluate robustness of the pathway enrichment. The single Benjamini- Hochberg corrected p-value > 0.05 possibly indicating a false positive result (PDGF signaling) is underlined